In terms of immunogenicity, vulvovaginal melanomas demonstrate lower rates of PD-L1 positivity (18%) compared with cutaneous melanomas (29.5%) and overall reduced expression of immune checkpoint genes. The gene discussed is CD274; the disease is cutaneous melanoma.